Alveron Pharmaceuticals is a Rotterdam based clinical-stage biopharmaceutical company developing OKL-1111. a small molecule injectable anticoagulant and platelet inhibitor reversal agent for intracerebral hemorrhage. Alveron’s vision is to bring to market the first single agent, single dose therapeutic option for patients experiencing brain bleeds that does not require identification of the active agent in order to determine whether the reversal agent is indicated for use. Currently available reversal agents are anticoagulant-specific, and therefore require time and operational complexity to indicate and dose, lengthening the period from index event to bleeding reversal substantially. A broad-spectrum reversal agent, particularly one that can inhibit antiplatelet agents for which no reversal agent yet exists, would potentially provide an important reduction in hemorrhage expansion, mass effect, mortality, and post-stroke morbidity in this high unmet need population.
Antag Therapeutics is a Copenhagen-based preclinical stage biotechnology company focused on developing therapies for dietary-related metabolic diseases. The company’s current lead therapy is a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist for inducing weight loss in obese patients with Type-2 Diabetes. The Company’s technology is based upon decades of incretin physiology and diabetes research from the laboratories of Professors Mette Rosenkilde and Jens Juul Holst at the University of Copenhagen, which played a pivotal role in the establishment of dipeptidyl peptidase 4 (DPP-4) inhibitor and glucagon-like peptide-1 (GLP-1) agonist drug classes.
Basking Biosciences, Inc. is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). The company was founded in 2019 by Bruce Sullenger, PhD of Duke University and Shahid Nimjee, MD, PhD of The Ohio State University. Basking is focused on exploiting the properties of RNA biology to develop aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis. BB-031 is an RNA aptamer that binds to von Willebrand Factor (vWF) and has demonstrated potent vessel recanalization ability across multiple murine and canine preclinical models. BB-025 is a sequence specific reversal oligonucleotide that rapidly and durably neutralizes the pharmacologic effect of BB-031.
Comanche Biopharma is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. The Company’s purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining natural pregnancy and allowing for fetal maturation. Comanche envisions a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective and sustainable.
Epirium is a clinical stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue regeneration, potentially resulting in novel and clinically significant therapeutic approaches to currently intractable neuromuscular and neurodegenerative diseases, including primary and secondary cardiomyopathies. The Company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium intends to advance its first clinical candidate (EB 002) this year, initially in Becker muscular dystrophy, followed by drug development targeting other progressive neuromuscular and neurodegenerative disorders associated with mitochondrial depletion.
HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
IsomAb is a pre-clinical company developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by the company Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
The mechanism of action of ISM-001 is unique and would be the only treatment to target a key pathway and reduce harmful serum levels of VEGF165b. ISM-001 would provide an unparalleled approach to treatment of patients including those with Type II diabetes mellitus and peripheral vascular disease at risk of amputation.
Mosanna Therapeutics is developing MOS-118, a first-in-class pharmacologic upper airway dilator muscle activator for the treatment of obstructive sleep apnea (OSA). MOS-118 is an intranasally delivered pan-K+ channel inhibitor that acts locally on the pressure sensing nerves located in the nasopharynx. It’s intranasal route of administration and mechanism of action result in minimal systemic exposure, offering a patient-friendly, safe and effective treatment for those unable or unwilling to tolerate CPAP.
